CLINICAL_TRIALS
trial_result
· 2011-04-13
Clinical Trial Update: Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis [Phase 2]
Summary
Phase 2 trial evaluating the safety and efficacy of a 12-week two-dose tiotropium Respimat regimen in cystic fibrosis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2011-04-13